ArriVent BioPharma, Inc. (AVBP)
NASDAQ: AVBP · Real-Time Price · USD
27.45
+0.86 (3.23%)
Nov 22, 2024, 4:00 PM EST - Market closed

Company Description

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States.

It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.

In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002.

It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib.

The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

ArriVent BioPharma, Inc.
ArriVent BioPharma logo
Country United States
Founded 2021
IPO Date Jan 26, 2024
Industry Biotechnology
Sector Healthcare
Employees 40
CEO Zhengbin Yao

Contact Details

Address:
18 Campus Boulevard, Suite 100
Newtown Square, Pennsylvania 19073
United States
Phone 628-277-4836
Website arrivent.com

Stock Details

Ticker Symbol AVBP
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $18.00
CIK Code 0001868279
ISIN Number US04272N1028
SIC Code 2834

Key Executives

Name Position
Dr. Zhengbin Yao Ph.D. Co-Founder, Chairman, President and Chief Executive Officer
Dr. Stuart Lutzker M.D., Ph.D. Co-Founder, President of Research and Development and Director
Robin LaChapelle M.A. Co-Founder and Chief Operating Officer
Winston Kung M.B.A. Chief Financial Officer and Treasurer
Yang Wang Ph.D. Chief Technology Officer
James Paul Kastenmayer J.D., Ph.D. General Counsel and Secretary
Meghna Chowdary Senior Vice President of Commercial Strategy

Latest SEC Filings

Date Type Title
Nov 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 10-Q Quarterly Report
Nov 14, 2024 8-K Current Report
Nov 12, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 12, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 8, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Oct 24, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Oct 11, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Sep 9, 2024 8-K Current Report
Aug 14, 2024 10-Q Quarterly Report